Kathy Ivey, Ph.D.

Kathy Ivey brings nearly 25 years of experience in the discovery of transformative product candidates for heart disease. For the past several years, she has overseen the discovery and preclinical testing efforts that resulted in Tenaya’s TN-201 and TN-401 gene therapy product candidates. Dr. Ivey has also led the company’s capsid engineering efforts to create novel adeno-associated capsids with greater selectivity to deliver genetic medicines with the potential to prevent or reverse specific forms of cardiac disease. In addition, she has been responsible for much of Tenaya’s most cutting-edge endeavors, including early-stage gene editing and cardiac regeneration programs. Previously, Dr. Ivey was a Staff Researcher at The Gladstone Institutes where she directed the Gladstone Stem Cell Core and worked with Tenaya’s scientific co-founder, Deepak Srivastava, MD., and aided in Tenaya’s formation. Dr. Ivey is trained in Molecular and Cell Biology and holds a B.S. from Texas A&M University and Ph.D. from UT Southwestern Medical Center where she completed her thesis work within the Molecular Biology Department chaired by Tenaya co-founder, Eric Olson, Ph.D.